Talk:Abnormal Development - Thalidomide: Difference between revisions

From Embryology
Line 46: Line 46:


PMID: 17409565  
PMID: 17409565  
:"Thalidomide (1) was developed in the 1950s as a nontoxic sedative/hypnotic drug, but was withdrawn from the market in the early 1960s because of its teratogenicity.1—5) However, it was subsequently identified as an effective agent for the treatment of multiple myeloma (MM), AIDS, Hansen’s dis- ease, and various cancers.1—5) The US Food and Drug Ad- ministration (FDA) approved it first for the treatment of ery- thema nodosum in Hansen’s disease in 1998, and then, in combination with dexamethasone, for the treatment of MM in 2006."


----
----

Revision as of 10:10, 9 September 2010

Historic Reference

Arch Environ Health. 1962 Aug;5:100-5. Thalidomide embryopathy. LENZ W, KNAPP K.

PMID: 14464040 [PubMed - indexed for MEDLINE] http://www.ncbi.nlm.nih.gov/pubmed/14464040

References

Thalidomide inhibits inflammatory and angiogenic activation of human intestinal microvascular endothelial cells (HIMEC).

Rafiee P, Stein DJ, Nelson VM, Otterson MF, Shaker R, Binion DG. Am J Physiol Gastrointest Liver Physiol. 2010 Feb;298(2):G167-76. Epub 2009 Nov 19. PMID: 19926820

Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation.

Therapontos C, Erskine L, Gardner ER, Figg WD, Vargesson N. Proc Natl Acad Sci U S A. 2009 May 26;106(21):8573-8. Epub 2009 May 11. PMID: 19433787

Thalidomide as a multi-template for development of biologically active compounds.

Hashimoto Y. Arch Pharm (Weinheim). 2008 Sep;341(9):536-47. Review. PMID: 18389516

Shedding light on an old mystery: thalidomide suppresses survival pathways to induce limb defects.

Cell Cycle. 2008 May 1;7(9):1121-7. Epub 2008 Feb 14.

Knobloch J, Rüther U.

Institute for Animal Developmental and Molecular Biology, Heinrich-Heine-University, Düsseldorf, Germany. juergen.knobloch@uk-koeln.de Abstract Many hypotheses have been proposed to explain the molecular mechanism of thalidomide teratogenicity, in particular regarding to limb defects. Most experimental evidence in vivo has been provided for a model that suggests the generation of oxidative stress by thalidomide with subsequent downregulation of Wnt and Akt survival pathways. As a consequence apoptosis is induced during early embryonic limb development resulting in limb truncations. Here we summarize and discuss the relevant data supporting this hypothesis. We extend this model by presenting new data demonstrating an involvement of the transcription factors Tbx5 and Sall4 in thalidomide-induced molecular pathology. Finally, we discuss a possible participation of other stress-responsive and/or pro-apoptotic transcription factors in the mechanism of thalidomide teratogenicity.

PMID: 18418038


Hydrolyzed metabolites of thalidomide: synthesis and TNF-alpha production-inhibitory activity.

Chem Pharm Bull (Tokyo). 2007 Apr;55(4):651-4. Nakamura T, Noguchi T, Miyachi H, Hashimoto Y.

Institute of Molecular & Cellular Biosciences, The University of Tokyo, Japan. Abstract

Putative hydrolyzed metabolites of thalidomide were prepared and characterized, and their inhibitory activity on tumor necrosis factor (TNF)-alpha production in the human monocytic leukemia cell line THP-1 was evaluated. Alpha-(2-Carboxybenzamido)glutarimide was a more potent TNF-alpha production inhibitor than thalidomide.

PMID: 17409565

"Thalidomide (1) was developed in the 1950s as a nontoxic sedative/hypnotic drug, but was withdrawn from the market in the early 1960s because of its teratogenicity.1—5) However, it was subsequently identified as an effective agent for the treatment of multiple myeloma (MM), AIDS, Hansen’s dis- ease, and various cancers.1—5) The US Food and Drug Ad- ministration (FDA) approved it first for the treatment of ery- thema nodosum in Hansen’s disease in 1998, and then, in combination with dexamethasone, for the treatment of MM in 2006."


Benegbi M. 45 years later...where do we stand? Can J Clin Pharmacol. 2007 Winter;14(1):e37-9.

Li PK, Pandit B, Sackett DL, Hu Z, Zink J, Zhi J, Freeman D, Robey RW, Werbovetz K, Lewis A, Li C. A thalidomide analogue with in vitro antiproliferative, antimitotic, and microtubule-stabilizing activities. Mol Cancer Ther. 2006 Feb;5(2):450-6.

Research Groups

Japan

  • Hashimoto Y. - Institute of Molecular & Cellular Biosciences, The University of Tokyo, Japan.